Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the ...

Eli Lilly (LLY) recently entered a collaboration with Gate Bioscience to develop molecular gate therapeutics, a move that ...

Eli Lilly is walking through the Gate, inking a deal worth up to $856 million with a biotech aiming to build out a new small ...

Eli Lilly ( LLY 0.64%) has been one of the best-performing pharmaceutical leaders in the past five years. Thanks to strong ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

The transaction will allow Lilly to expand its pain management pipeline with the addition of STC-004, a Phase 2-ready Nav1.8 inhibitor being studied for the treatment of pain.

Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its shares.

The sale agreement will see Eli Lilly pay up to $1bn to buy SiteOne, ... The acquisition adds to Eli Lilly’s pain pipeline, which includes four candidates. A Phase I trial (ACTRN12624000642583) ...

Eli Lilly LLY 1.34 % increase; green up pointing triangle agreed to acquire Verve Therapeutics VERV-0.37 % decrease; red down pointing triangle for about $1 billion upfront, adding a potential ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 trillion stock and the first healthcare company to do so. Trading at $852 per ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and the risks. Click for my LLY stock update.